Assignee
BIOAGE LABS INC
US·11 granted patents·14 pending applications·15 citations·filing 2018–2025
Top patents by PatentIndex Score
25 records- 0193US11787805B2N-oxide inhibitors of NLRP3 inflammasomeBIOAGE LABS INC·Filed 2023·Granted Oct 17, 2023·3 cites·29 claims
- 0293US11708334B2Inhibitors of NLRP3 inflammasomeBIOAGE LABS INC·Filed 2022·Granted Jul 25, 2023·3 cites·18 claims
- 0392US12215087B2Inhibitors of NLRP3 inflammasomeBIOAGE LABS INC·Filed 2023·Granted Feb 4, 2025·1 cites·6 claims
- 0490US12129251B2N-oxide inhibitors of NLRP3 inflammasomeBIOAGE LABS INC·Filed 2023·Granted Oct 29, 2024·1 cites·25 claims
- 0587US11702391B2Inhibitors of NLRP3 inflammasomeBIOAGE LABS INC·Filed 2022·Granted Jul 18, 2023·1 cites·9 claims
- 0683US12421196B2Inhibitors of NLRP3 inflammasomeBIOAGE LABS INC·Filed 2023·Granted Sep 23, 2025·0 cites·18 claims
- 0781US11445981B1Survival prediction using methylomic profilesBIOAGE LABS INC·Filed 2018·Granted Sep 20, 2022·5 cites·19 claims
- 0881US2023365507A1Inhibitors of nlrp3 inflammasomeBIOAGE LABS INC·Filed 2023·Application pending·0 cites
- 0979US2023212252A1RAGE Fusion Proteins with Improved Stability and Ligand Binding Affinity and Uses ThereofBIOAGE LABS INC·Filed 2022·Application pending·0 cites
- 1079US2025092037A1N-oxide inhibitors of nlrp3 inflammasomeBIOAGE LABS INC·Filed 2024·Application pending·0 cites
- 1177US11535661B2RAGE fusion proteins with improved stability and ligand binding affinity and uses thereofBIOAGE LABS INC·Filed 2021·Granted Dec 27, 2022·0 cites·18 claims
- 1271US10913784B2RAGE fusion proteins with improved stability and ligand binding affinity and uses thereofBIOAGE LABS INC·Filed 2019·Granted Feb 9, 2021·0 cites·15 claims
- 1369US2021188940A1RAGE Fusion Proteins with Improved Stability and Ligand Binding Affinity and Uses ThereofBIOAGE LABS INC·Filed 2020·Application pending·0 cites
- 1465US2025155452A1NLRP3 Variants & Library Screen for NLRP3 Inhibitors with the SameBIOAGE LABS INC·Filed 2024·Application pending·0 cites
- 1565US2025084080A1Crystalline and salt forms of an nlrp3 inhibitorBIOAGE LABS INC·Filed 2024·Application pending·0 cites
- 1663US11881311B1Survival prediction using metabolomic profilesBIOAGE LABS INC·Filed 2018·Granted Jan 23, 2024·1 cites·18 claims
- 1763US2024105340A1Survival prediction using metabolomic profilesBIOAGE LABS INC·Filed 2023·Application pending·0 cites
- 1863US2024116933A1Indazole and pyrazolopyridine compounds as inhibitors of nlrp3 inflammasomeBIOAGE LABS INC·Filed 2023·Application pending·0 cites
- 1960US2024366602A1Combination therapy of apelin receptor agonist and glp-1 receptor agonist for treating a disease or condition associated with weight gainBIOAGE LABS INC·Filed 2024·Application pending·0 cites
- 2056US2024041878A1Apelin receptor modulators for treatment of a disorder or disease associated with bbb permeabilityBIOAGE LABS INC·Filed 2023·Application pending·0 cites
- 2155US2024122926A1Apelin receptor modulators for treating muscle conditionsBIOAGE LABS INC·Filed 2023·Application pending·0 cites
- 2249US2024252493A1Apelin Receptor Modulators for Treating Age-Related Muscle ConditionsBIOAGE LABS INC·Filed 2022·Application pending·0 cites
- 2345US12509459B2Inhibitors of NLRP3 inflammasomeBIOAGE LABS INC·Filed 2025·Granted Dec 30, 2025·0 cites·29 claims
- 2444US2021353612A1Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditionsBIOAGE LABS INC·Filed 2021·Application pending·0 cites
- 2534US2019114390A1Drug repurposing based on deep embeddings of gene expression profilesBIOAGE LABS INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when BIOAGE LABS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →